BC Innovations | Jun 5, 2014
Strategy

Sanford-Burnham goes fourth

Sanford-Burnham Medical Research Institute 's outreach to industry has resulted historically in deals focused either on a narrow range of projects or the work of individual investigators, but the institute also has been seeking broader...
BC Week In Review | Oct 3, 2011
Clinical News

Cholestagel regulatory update

Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX;VRX, Mississauga, Ontario) said Health Canada approved an NDS for Cholestagel colesevelam to treat hypercholesterolemia. In February, Sanofi's Genzyme Corp. subsidiary granted Valeant rights to market the non-absorbed bile acid...
BC Week In Review | Aug 1, 2011
Clinical News

Welchol colesevelam regulatory update

FDA approved an sNDA from Daiichi for an oral suspension formulation of Welchol colesevelam to be mixed with fruit juice or diet soft drinks to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary...
BC Week In Review | Jul 11, 2011
Company News

Daiichi Sankyo, Impax, Sanofi metabolic news

Impax, Daiichi and Sanofi's Genzyme Corp. subsidiary settled a pair of 2010 suits filed in the U.S. District Court for the District of Delaware related to Imapx's oral suspension and tablet generic versions of Daiichi's...
BC Week In Review | Apr 25, 2011
Company News

Watson, Daiichi Sankyo, sanofi-aventis metabolic news

Daiichi and sanofi-aventis' Genzyme Corp. subsidiary filed suit against Watson in the U.S. District Court for the District of Delaware alleging that Watson's ANDA for generic colesevelam tablets infringes U.S. Patent Nos. 5,607,669 and 5,693,675...
BC Week In Review | Feb 14, 2011
Company News

Genzyme, Valeant Pharmaceuticals sales and marketing update

Genzyme granted Valeant's Biovail Laboratories International SRL subsidiary rights to market Cholestagel colesevalem in Canada. The non-absorbed bile acid sequestrant is approved to treat hypercholesterolemia. Genzyme will receive $2 million up front and is eligible...
BC Week In Review | Jul 19, 2010
Clinical News

Welchol: Phase IV data

In a double-blind, international Phase IV trial in 286 treatment-naive Type II diabetics, 3.75 g/day Welchol plus metformin met the primary endpoint of significantly reducing mean HbA1c from baseline to week 16 vs. placebo plus...
BC Week In Review | May 3, 2010
Clinical News

Welchol colesevelam: Phase IV data

Data from a double-blind Phase IV trial in 216 patients showed that 3.75 g/day Welchol met the primary endpoint of significantly reducing LDL cholesterol from baseline to week 16 vs. placebo (13.9% reduction vs. 1.7%...
BC Week In Review | Mar 1, 2010
Clinical News

WelChol colesevelam regulatory update

The European Medicines Agency's CHMP issued a positive opinion to extend the indication of Genzyme's Cholestagel colesevelam to include combination treatment with ezetimibe, with or without a statin, in adults with primary hypercholesterolemia, including patients...
BC Week In Review | Oct 12, 2009
Clinical News

Welchol colesevelam regulatory update

FDA approved an sNDA from Daiichi for Welchol colesevelam as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls ages 10-17 with heterozygous familial hypercholesterolemia (HeFH)...
Items per page:
1 - 10 of 83